66 episodes

This Life Science focused podcast brings together Xtalks editorial staff to share insights into the latest B2B industry news. Xtalks connects professionals in the life science, medical device, and food industries with useful content like webinars, job opening, articles and virtual meetings.

Xtalks Life Science Podcast Xtalks

    • Science
    • 5.0 • 3 Ratings

This Life Science focused podcast brings together Xtalks editorial staff to share insights into the latest B2B industry news. Xtalks connects professionals in the life science, medical device, and food industries with useful content like webinars, job opening, articles and virtual meetings.

    Eli Lilly's Olumiant FDA Approved for Alopecia + Alnylam's RNAi Drug Amvuttra Approved for Rare Protein Disorder

    Eli Lilly's Olumiant FDA Approved for Alopecia + Alnylam's RNAi Drug Amvuttra Approved for Rare Protein Disorder

    In this episode, Ayesha and the team talked about the FDA approval of Eli Lilly’s JAK inhibitor Olumiant for the treatment of alopecia areata, also commonly just known as alopecia. The drug has become the first approved systemic treatment for the autoimmune disorder that causes patchy hair loss. Hear about how alopecia has received mainstream recognition because of a recent infamous Hollywood incident and the importance of raising awareness about rare diseases like alopecia.
    Ayesha also discussed the FDA approval of Alnylam’s RNAi therapeutic Amvuttra for the treatment of polyneuropathy associated with a rare protein disorder called hereditary transthyretin-mediated (ATTR) amyloidosis. Hear about how the drug is also being evaluated for another type of (ATTR cardiomyopathy) and the other big players in the ATTR space including Pfizer and AstraZeneca.
    Read the full articles here: 
    Eli Lilly’s Olumiant Wins FDA Approval as First Systemic Treatment for Alopecia Areata
    Amvuttra RNAi Therapeutic Wins FDA Approval for Rare Genetic Protein Disorder
    For more life science and medical device content, visit the Xtalks Vitals homepage.
    Follow Us on Social Media
    Twitter: @Xtalks
    Instagram: @Xtalks
    Facebook: https://www.facebook.com/Xtalks.Webinars/
    LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
    YouTube: https://www.youtube.com/c/XtalksWebinars/featured

    • 23 min
    More Positive Data for Tirzepatide Weight Loss Injection + Sandoz's Global Biosimilars Awareness Campaign

    More Positive Data for Tirzepatide Weight Loss Injection + Sandoz's Global Biosimilars Awareness Campaign

    In this episode, Ayesha discussed new data shared by Eli Lilly for its weight loss injection tirzepatide. The drug was recently approved (under the brand name Mounjaro) by the US Food and Drug Administration (FDA) for the treatment of type 2 diabetes. The dual GIP/GLP-1 receptor agonist also has weight loss effects and recent analyses presented at the American Diabetes Association’s 82nd Scientific Sessions showed that almost 40 percent of participants lost a quarter of their body weight. Hear more about the newest data and industry predictions for tirzepatide as a rival to Novo Nordisk’s GLP-1 receptor agonist weight loss injection Wegovy.
    The editorial team also discussed a new global biosimilars awareness campaign launched by Sandoz, Novartis’ biosimilars and generics drug division. The campaign is called Act4Biosimilars and will focus on improving the acceptability and accessibility to biosimilars, among factors, by 30 percent in over 30 countries by the year 2030. The campaign is aimed at addressing global health inequity and inequality by increasing access to advanced medicines like biosimilars. The team discussed the importance of education around biosimilars to help increase their acceptability and uptake.
    Read the full articles here: 
    More Positive Data for Eli Lilly’s Diabetes and Weight Loss Injection Tirzepatide
    Novartis’ Sandoz Launches Biosimilars Awareness Campaign to Improve Biosimilars Adoption Worldwide
    For more life science and medical device content, visit the Xtalks Vitals homepage.
    Follow Us on Social Media
    Twitter: @Xtalks
    Instagram: @Xtalks
    Facebook: https://www.facebook.com/Xtalks.Webinars/
    LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
    YouTube: https://www.youtube.com/c/XtalksWebinars/featured

    • 23 min
    Interview with Georgia Tech’s Dr. Woon-Hong Yeo About a New Smart Stent Platform for Wireless Vascular Monitoring

    Interview with Georgia Tech’s Dr. Woon-Hong Yeo About a New Smart Stent Platform for Wireless Vascular Monitoring

    This episode features an interview with Georgia Institute of Technology researcher Dr. Woon-Hong Yeo who has helped lead a team of researchers to develop a novel vascular monitoring system based on a specially designed smart stent. Hear about how the implantable smart stent system offers real-time and continuous monitoring of metrics like blood pressure and blood flow, as well as Dr. Yeo’s personal motivation for creating the vascular monitoring system to help people monitor their cardiac health. Dr. Yeo is a Woodruff Faculty Fellow; Associate Professor in Mechanical Engineering and Biomedical Engineering; and the Director of the Center for Human-Centric Interfaces and Engineering at Georgia Tech.
    For more life science and medical device content, visit the Xtalks Vitals homepage.
    Follow Us on Social Media
    Twitter: @Xtalks
    Instagram: @Xtalks
    Facebook: https://www.facebook.com/Xtalks.Webinars/
    LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
    YouTube: https://www.youtube.com/c/XtalksWebinars/featured

    • 23 min
    Interview with Dr. Samantha Dale Strasser, CSO and Co-Founder of Transomics Drug Discovery Start-Up "Pepper Bio"

    Interview with Dr. Samantha Dale Strasser, CSO and Co-Founder of Transomics Drug Discovery Start-Up "Pepper Bio"

    In this episode, Ayesha and the editorial team spoke with Dr. Samantha Dale Strasser, chief scientific officer and co-founder of biotech start-up Pepper Bio. The company is working to develop therapeutics in the areas of oncology, neurodegenerative disease and inflammatory conditions using a ‘transomics’ drug discovery approach. This involves the integrated analysis of several layers of biological data, including genomic, proteomic, transcriptomic and phosphoproteomic data using novel transomics technologies involving lab methods and AI approaches. Hear more about Pepper Bio as well as Dr. Strasser’s journey from academia to the biotech industry.
    For more life science and medical device content, visit the Xtalks Vitals homepage.
    Follow Us on Social Media
    Twitter: @Xtalks
    Instagram: @Xtalks
    Facebook: https://www.facebook.com/Xtalks.Webinars/
    LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
    YouTube: https://www.youtube.com/c/XtalksWebinars/featured

    • 27 min
    FDA Approves New Type 2 Diabetes Injection Mounjaro + US Reports First Case of Monkeypox

    FDA Approves New Type 2 Diabetes Injection Mounjaro + US Reports First Case of Monkeypox

    In this episode, Ayesha discussed the FDA approval of Eli Lilly’s diabetes injection Mounjaro (tirzepatide) for the treatment of adults with type 2 diabetes This is a great advancement in the diabetes space as Mounjaro is a first-in-class medicine that targets the activity of two hormones involved in hunger and blood sugar control (GLP-1 and GIP). With the approval, Eli Lilly will be giving Novo Nordisk’s blockbuster diabetes injection Ozempic some tough competition. Hear about the projected sales of Mounjaro, data from studies that led to its approval and its impact from a patient perspective.
    Ayesha also talked about the current monkeypox outbreak as clusters of cases continue to be reported in countries in Europe and North America. The US recently reported its first case of monkeypox, and all cases so far are linked to international travel. Learn more about monkeypox and how health authorities are asking people not to panic as most cases are mild and treatable. Also hear about how Britain is offering the smallpox vaccine to healthcare workers to help prevent infection from the monkeypox virus.
    Read the full articles here: 
    Mounjaro (tirzepatide), Eli Lilly’s Highly Awaited Type 2 Diabetes Injection Gets FDA Nod
    Monkeypox Case Reported in the US as Virus Spreads Across Europe and North America
    For more life science and medical device content, visit the Xtalks Vitals homepage.
    Follow Us on Social Media
    Twitter: @Xtalks
    Instagram: @Xtalks
    Facebook: https://www.facebook.com/Xtalks.Webinars/
    LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
    YouTube: https://www.youtube.com/c/XtalksWebinars/featured

    • 25 min
    Messaging Program Improves Lifestyle Among Heart Attack Survivors + FDA Places Stricter Restrictions on Janssen COVID-19 Vaccine

    Messaging Program Improves Lifestyle Among Heart Attack Survivors + FDA Places Stricter Restrictions on Janssen COVID-19 Vaccine

    In this episode, Ayesha discussed a new study that evaluated a text messaging program designed to improve medication adherence and lifestyle factors among heart attack survivors. While the program did not lead to improvements in medication adherence, it did have a positive impact on lifestyle factors like diet. Hear more about the study and the importance of managing heart attack risk factors like hypertension and diabetes. This is especially relevant on World Hypertension Day (May 17) and May Measurement Month, which bring awareness to the importance of accurately measuring blood pressure.
    Ayesha also talked about the FDA’s decision to place stricter restrictions on the use of Janssen/Johnson & Johnson’s COVID-19 vaccine given continuing concerns of the rare but serious side effect of blood clots. Hear about why the FDA revised the vaccine’s authorization, and why the FDA maintains that the vaccine’s benefits outweigh any known or potential risks.
    Read the full articles here: 
    How Heart Attack Survivors Can Improve Lifestyle Factors with a Text Messaging Program
    FDA Puts Further Restrictions on Use of Janssen/Johnson & Johnson COVID-19 Vaccine
    For more life science and medical device content, visit the Xtalks Vitals homepage.
    Follow Us on Social Media
    Twitter: @Xtalks
    Instagram: @Xtalks
    Facebook: https://www.facebook.com/Xtalks.Webinars/
    LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
    YouTube: https://www.youtube.com/c/XtalksWebinars/featured

    • 25 min

Customer Reviews

5.0 out of 5
3 Ratings

3 Ratings

Phoeptar ,

Great show, great hosts

This is now added to the other science and technology shows I listen to weekly. The hosts make it, their chemistry and individual knowledge base they bring to the discussions make it very enjoyable.

Top Podcasts In Science

Jordan Harbinger
Alie Ward
Vox
Hidden Brain
Sam Harris
CBC Podcasts

You Might Also Like